Included in the formulation
АТХ:M.04.A.A.01 Allopurinol
M.04.A.B.03 Benzbromarone
Pharmacodynamics:The active substances in combination have a hypouricemic and anti-arthritic effect. Allopurinol inhibits xanthine oxidase, reducing the formation of uric acid. Benzbromarone enhances the excretion of uric acid by the kidneys. The drug reduces the elevated level of uric acid in the blood plasma, eliminates and prevents its deposition in the form of salts, prevents kidney damage and attacks of gout.
Pharmacokinetics:After ingestion, absorption from the gastrointestinal tract is incomplete. Cmax in blood plasma is reached after about 2-4 hours Benzbromarone is highly associated with plasma proteins. Metabolised in the liver and excreted mainly with feces, in small amounts determined in urine.
Indications:Hyperuricemia of various genesis, gout.
IV.E70-E90.E79.0 Hyperureukia without signs of inflammatory arthritis and gouty nodes
Contraindications:Hypersensitivity to the drug components, hemochromatosis, severe renal dysfunction (with creatinine level in the serum above 132.6 μmol / l (1.5 mg / 100 ml) or with a glomerular filtration rate below 40 ml / min), pregnancy, breastfeeding, age (up to 14 years).
Carefully:In severe renal impairment (serum creatinine level more than 1.5 mg and glomerular filtration rate below 40 ml / min) do not use (recommended allopurinol without benzbromarone).
Pregnancy and lactation:The combination of allopurinol and benzbromarone has direct contraindications for use in pregnancy and lactation.
Dosing and Administration:Inside, for 1-3 tables. the day after eating, with the mandatory intake of at least 1.5-2 liters of fluid per day (under the control of diuresis). Treatment should begin with 1 tab. per day with a gradual increase in the dose.
Side effects:Gastrointestinal disorders, allergic reactions, diarrhea, vasculitis with skin manifestations and fever, liver and kidney damage, changes in the blood picture (leukopenia, thrombocytopenia),
Overdose:Treatment symptomatic
Interaction:With the simultaneous use of anticoagulants, it is possible to intensify their action.
With the simultaneous use of acetylsalicylic acid in low doses, the therapeutic effect of benzbromarone decreases.
Special instructions:The first reception of benzbromarone can cause an acute attack of gout or arthralgia,therefore a combination with NSAIDs is recommended.
It is necessary to control the content of uric acid in the blood and urine after 1 month of treatment.
To prevent the formation of stones in the urinary tract, the patient should drink liquids not <2 l / day. The pH values of urine before the normalization of serum uric acid level are established in the range of 6.4-6.8.
If diarrhea occurs, the treatment should be discontinued before normalization of the stool, with the recommencement of treatment, benzbromarone is recommended for use in a reduced dose. In the case of repeated development of diarrhea treatment should be discontinued.
During the treatment period, alcohol consumption should be eliminated and the intake of food with a high purine content should be strictly limited.